Yongjuan Zhao

Prof. Dr. Yongjuan Zhao

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in iScience
Verified
Journal Article
Open access
ZZZhi Ying Zhao
Zhi Ying Zhao
XXXu Jie Xie
Xu Jie Xie
WLWan Hua Li
Wan Hua Li
JLJun Liu
Jun Liu
ZCZhe Chen
Zhe Chen
YZYongjuan Zhao
Yongjuan Zhao
SARM1, an NAD-utilizing enzyme, regulates axonal degeneration. We show that CZ-48, a cell-permeant mimetic of NMN, activated SARM1 in vitro and in cellulo to cyclize NAD and produce a Ca2+ messenger, cADPR, with similar efficiency as NMN. Knockout of NMN-adenylyltransferase elevated cellular NMN and activated SARM1 to produce cADPR, confirming NMN was its endogenous activator. Determinants for the activating effects and cell permeability of CZ-48 were identified. CZ-48 activated SARM1 via a conformational change of the auto-inhibitory domain and dimerization of its catalytic domain. SARM1 catalysis was similar to CD38, despite having no sequence similarity. Both catalyzed similar set of reactions, but SARM1 had much higher NAD-cyclizing activity, making it more efficient in elevating cADPR. CZ-48 acted selectively, activating SARM1 but inhibiting CD38. In SARM1-overexpressing cells, CZ-48 elevated cADPR, depleted NAD and ATP, and induced non-apoptotic death. CZ-48 is a specific modulator of SARM1 functions in cells.

11 September 2012 in Science Signaling
Verified
Journal Article
Closed access
PDF file
YZYongjuan Zhao
Yongjuan Zhao
CLConnie Mo Ching Lam
Connie Mo Ching Lam
HLHon Cheung Lee
Hon Cheung Lee
The transmembrane enzyme CD38, a multifunctional protein ubiquitously present in cells, is the main enzyme that synthesizes and hydrolyzes cyclic adenosine 5′-diphosphate-ribose (cADPR), an intracellular Ca2+-mobilizing messenger. CD38 is thought to be a type II transmembrane protein with its carboxyl-terminal catalytic domain located on the outside of the cell; thus, the mechanism by which CD38 metabolizes intracellular cADPR has been controversial. We developed specific antibodies against the amino-terminal segment of CD38 and showed that two opposing orientations of CD38, type II and type III (which has its catalytic domain inside the cell), were both present on the surface of HL-60 cells during retinoic acid–induced differentiation. When activated by interferon-γ, human primary monocytes and the monocytic U937 cell line exhibited a similar co-distribution pattern. Site-directed mutagenesis experiments showed that the membrane orientation of CD38 could be converted from a mixture of type II and type III orientations to all type III by mutating the cationic amino acid residues in the amino-terminal segment of CD38. Expression of type III CD38 construct in transfected cells led to increased intracellular concentrations of cADPR, indicating the importance of the type III orientation of CD38 to its Ca2+ signaling function. The identification of these two forms of CD38 suggests that flipping the catalytic domain from the outside to the inside of the cell may be a mechanism regulating its signaling activity.

22 December 2017 in ACS Chemical Biology
Verified
Journal Article
Closed access
YJYanhong Jiang
Yanhong Jiang
QDQiwen Deng
Qiwen Deng
HZHui Zhao
Hui Zhao
MXMingsheng Xie
Mingsheng Xie
LCLongjian Chen
Longjian Chen
Zigang LiZigang Li
Zigang Li

5 September 2018 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
NANa An
Na An
YHYun Nan Hou
Yun Nan Hou
QZQiao Xia Zhang
Qiao Xia Zhang
TLTing Li
Ting Li
QZQiong Li Zhang
Qiong Li Zhang
XDXin Du
Xin Du

4 May 2021 in eLife
Verified
Journal Article
Open access
WLWan Hua Li
Wan Hua Li
KHKe Huang
Ke Huang
YCYang Cai
Yang Cai
QWQian Wen Wang
Qian Wen Wang
WZWen Jie Zhu
Wen Jie Zhu
YZYongjuan Zhao
Yongjuan Zhao
SARM1 regulates axonal degeneration through its NAD-metabolizing activity and is a drug target for neurodegenerative disorders. We designed and synthesized fluorescent conjugates of styryl derivative with pyridine to serve as substrates of SARM1, which exhibited large red shifts after conversion. With the conjugates, SARM1 activation was visualized in live cells following elevation of endogenous NMN or treatment with a cell-permeant NMN-analog. In neurons, imaging documented mouse SARM1 activation preceded vincristine-induced axonal degeneration by hours. Library screening identified a derivative of nisoldipine (NSDP) as a covalent inhibitor of SARM1 that reacted with the cysteines, especially Cys311 in its ARM domain and blocked its NMN-activation, protecting axons from degeneration. The Cryo-EM structure showed that SARM1 was locked into an inactive conformation by the inhibitor, uncovering a potential neuroprotective mechanism of dihydropyridines.

2 June 2016 in Scientific Reports
Verified
Journal Article
Open access
PDF file
TLTing Li
Ting Li
SQShali Qi
Shali Qi
MUMandy Unger
Mandy Unger
YHYun Nan Hou
Yun Nan Hou
QDQi Wen Deng
Qi Wen Deng
YZYongjuan Zhao
Yongjuan Zhao
CD38, as a cell surface antigen is highly expressed in several hematologic malignancies including multiple myeloma (MM) and has been proven to be a good target for immunotherapy of the disease. CD38 is also a signaling enzyme responsible for the metabolism of two novel calcium messenger molecules. To be able to target this multifunctional protein, we generated a series of nanobodies against CD38 with high affinities. Crystal structures of the complexes of CD38 with the nanobodies were solved, identifying three separate epitopes on the carboxyl domain. Chromobodies, engineered by tagging the nanobody with fluorescence proteins, provide fast, simple and versatile tools for quantifying CD38 expression. Results confirmed that CD38 was highly expressed in malignant MM cells compared with normal white blood cells. The immunotoxin constructed by splicing the nanobody with a bacterial toxin, PE38 shows highly selective cytotoxicity against patient-derived MM cells as well as the cell lines, with half maximal effective concentration reaching as low as 10−11 molar. The effectiveness of the immunotoxin can be further increased by stimulating CD38 expression using retinoid acid. These results set the stage for the development of clinical therapeutics as well as diagnostic screening for myeloma.